Key Takeaway: Precision BioSciences reported its first quarter 2025 financial results, highlighting new clinical data for two programs that utilize ARCUS technology. The company presented initial safety data from the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the EASL conference. The results validate the safety and efficacy of their in vivo gene editing approach.
Price reaction · baseline $4.95 (2025-05-14 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-8.1%
day 1
-4.8%
day 3
-1.4%
Market Sentiment Analysis
POSITIVE FACTORS
New clinical data announced for two programs.
Validation of safety and efficacy for in vivo gene editing.
Initial data from the Phase 1 ELIMINATE-B trial shows promise.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision’s in vivo gene editing approach – Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing
Frequently Asked Questions
What did Precision BioSciences announce?
The company announced new clinical data for two programs and initial safety data from the ELIMINATE-B trial.
What is the ELIMINATE-B trial about?
The ELIMINATE-B trial is evaluating PBGENE-HBV, focusing on its safety and efficacy.
Where was the initial safety data presented?
The initial safety data was presented at the EASL conference.
What technology does Precision BioSciences utilize?
Precision uses ARCUS technology for its in vivo gene editing approach.